1. Home
  2. CVM
  3. CVM News

Latest Cel-Sci Corporation (CVM) News on August 24, 2025

CEL-SCI’s Multikine Head and Neck Cancer Immunotherapy Breakthrough Medicine Designation Filed in Saudi Arabia: Allows for Patient Access and Reimbursement/Sale Upon Granting of the Designation Which Takes Approximately 60 Days Based on SFDA Timeline
CVM

Business Wire

11 days ago

CEL-SCI’s Multikine Head and Neck Cancer Immunotherapy Breakthrough Medicine Designation Filed in Saudi Arabia: Allows for Patient Access and Reimbursement/Sale Upon Granting of the Designation Which Takes Approximately 60 Days Based on SFDA Timeline

FDA’s Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI’s Multikine to Address a Major Unmet Need in PD-L1 Negative Cancer Patients
CVM

Business Wire

2 months ago

FDA’s Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI’s Multikine to Address a Major Unmet Need in PD-L1 Negative Cancer Patients

CVM

MT Newswires

3 months ago

CEL-SCI Closes $5 Million Public Offering

CEL-SCI Announces Closing of Public Offering
CVM

Business Wire

3 months ago

CEL-SCI Announces Closing of Public Offering

CVM

MT Newswires

3 months ago

Top Midday Decliners

CVM

MT Newswires

3 months ago

Sector Update: Health Care

CVM

MT Newswires

3 months ago

Top Premarket Decliners

CVM

MT Newswires

3 months ago

CEL-SCI Prices Offering of 2 Million Shares

CEL-SCI Announces Pricing of Public Offering
CVM

Business Wire

3 months ago

CEL-SCI Announces Pricing of Public Offering

CVM

MT Newswires

3 months ago

CEL-SCI Announces Planned Public Offering; Shares Fall After Hours

CEL-SCI Announces Proposed Public Offering
CVM

Business Wire

3 months ago

CEL-SCI Announces Proposed Public Offering

CVM

MT Newswires

3 months ago

CEL-SCI Completes Saudi Breakthrough Medicine Designation Application for Multikine Cancer Drug

CEL-SCI’s Multikine Investigational Cancer Medicine Potentially Available for Commercialization by Summer 2025 in Saudi Arabia
CVM

Business Wire

3 months ago

CEL-SCI’s Multikine Investigational Cancer Medicine Potentially Available for Commercialization by Summer 2025 in Saudi Arabia

CVM

MT Newswires

3 months ago

CEL-SCI's Board Approves 1-for-30 Share Combination

CEL-SCI Announces Combination of Common Stock
CVM

Business Wire

3 months ago

CEL-SCI Announces Combination of Common Stock

CEL-SCI Reports Fiscal Second Quarter 2025 Financial Results
CVM

Business Wire

3 months ago

CEL-SCI Reports Fiscal Second Quarter 2025 Financial Results

CVM

Associated Press Finance

3 months ago

Cel-Sci: Fiscal Q2 Earnings Snapshot

CEL-SCI to File for Regulatory Approval of Multikine in Saudi Arabia—Pursuing Local Partnerships for Commercialization and Manufacturing to Serve Middle East and North Africa Market
CVM

Business Wire

4 months ago

CEL-SCI to File for Regulatory Approval of Multikine in Saudi Arabia—Pursuing Local Partnerships for Commercialization and Manufacturing to Serve Middle East and North Africa Market

New Study in the Scientific Journal "Cancer Cell" Supports CEL-SCI’s Strategy to Seek Early Approval for Multikine in Head and Neck Cancer Based on Pre-Surgical Tumor Responses
CVM

Business Wire

5 months ago

New Study in the Scientific Journal "Cancer Cell" Supports CEL-SCI’s Strategy to Seek Early Approval for Multikine in Head and Neck Cancer Based on Pre-Surgical Tumor Responses

CEL-SCI Reports New Data: Treatment with Multikine Resulted in up to 95% Improvement in Quality of Life for Head and Neck Cancer Patients
CVM

Business Wire

5 months ago

CEL-SCI Reports New Data: Treatment with Multikine Resulted in up to 95% Improvement in Quality of Life for Head and Neck Cancer Patients

CEL-SCI Announces Closing of $2.5 Million Offering
CVM

Business Wire

5 months ago

CEL-SCI Announces Closing of $2.5 Million Offering

CEL-SCI Announces Pricing of $2.5 Million Offering
CVM

Business Wire

5 months ago

CEL-SCI Announces Pricing of $2.5 Million Offering

CEL-SCI’s Head and Neck Cancer Registration Study Protocol Clears FDA Review—in Talks with Potential Partners Interested in Commercialization of Multikine
CVM

Business Wire

5 months ago

CEL-SCI’s Head and Neck Cancer Registration Study Protocol Clears FDA Review—in Talks with Potential Partners Interested in Commercialization of Multikine

Journal of the American Medical Association (JAMA) Study Provides Further Evidence that CEL-SCI’s Multikine Can Treat Unmet Need in ~70% of Head and Neck Patients Based on PD-L1 Expression
CVM

Business Wire

5 months ago

Journal of the American Medical Association (JAMA) Study Provides Further Evidence that CEL-SCI’s Multikine Can Treat Unmet Need in ~70% of Head and Neck Patients Based on PD-L1 Expression

CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial
CVM

Business Wire

6 months ago

CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial

CEL-SCI Reports Fiscal Q1 2025 Financial Results: Multikine Shows Pre-Surgical Tumor Elimination and Regression in Just 3 Weeks
CVM

Business Wire

6 months ago

CEL-SCI Reports Fiscal Q1 2025 Financial Results: Multikine Shows Pre-Surgical Tumor Elimination and Regression in Just 3 Weeks

CVM

Associated Press Finance

6 months ago

Cel-Sci: Fiscal Q1 Earnings Snapshot

CVM: Fiscal Year 2024 Results
CVM

Zacks Small Cap Research

6 months ago

CVM: Fiscal Year 2024 Results

CEL-SCI Reports Fiscal 2024 Results: Set to Commence Confirmatory Study That Could Bring New Standard of Care to Head & Neck Cancer
CVM

Business Wire

7 months ago

CEL-SCI Reports Fiscal 2024 Results: Set to Commence Confirmatory Study That Could Bring New Standard of Care to Head & Neck Cancer

CVM

MT Newswires

8 months ago

CEL-SCI Completes $5 Million 'Best Efforts' Stock Sale

CEL-SCI Announces Closing of $5 Million Offering
CVM

Business Wire

8 months ago

CEL-SCI Announces Closing of $5 Million Offering

CVM

MT Newswires

8 months ago

CEL-SCI Prices $5 Million Stock Offering

CEL-SCI Announces Pricing of $5 Million Public Offering
CVM

Business Wire

8 months ago

CEL-SCI Announces Pricing of $5 Million Public Offering

CEL-SCI Announces Proposed Public Offering of Common Stock
CVM

Business Wire

8 months ago

CEL-SCI Announces Proposed Public Offering of Common Stock

CEL-SCI Highlights Biological Rationale for the Use of Multikine in the Confirmatory Registration Head and Neck Cancer Study
CVM

Business Wire

8 months ago

CEL-SCI Highlights Biological Rationale for the Use of Multikine in the Confirmatory Registration Head and Neck Cancer Study

CVM

Zacks Small Cap Research

9 months ago

CVM: CRO Selected for Registrational Trial

U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025
CVM

Business Wire

10 months ago

U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025

FDA’s Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI’s Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer Patients
CVM

Business Wire

10 months ago

FDA’s Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI’s Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer Patients

CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer
CVM

Business Wire

a year ago

CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer

CEL-SCI’s Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation
CVM

Business Wire

a year ago

CEL-SCI’s Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation

CEL-SCI to Present New Data for Multikine® Head & Neck Cancer Immunotherapy at the European Society for Medical Oncology 2024 Congress
CVM

Business Wire

a year ago

CEL-SCI to Present New Data for Multikine® Head & Neck Cancer Immunotherapy at the European Society for Medical Oncology 2024 Congress

The UK’s Medicines & Healthcare Products Regulatory Agency Grants CEL-SCI a Pediatric Waiver, Bringing Multikine® One Step Closer to Future Marketing Clearance
CVM

Business Wire

a year ago

The UK’s Medicines & Healthcare Products Regulatory Agency Grants CEL-SCI a Pediatric Waiver, Bringing Multikine® One Step Closer to Future Marketing Clearance

CVM: Start Your Engines – FDA Green Lights Confirmatory Registration Study
CVM

Zacks Small Cap Research

a year ago

CVM: Start Your Engines – FDA Green Lights Confirmatory Registration Study

CEL-SCI Corporation Reports Third Quarter Fiscal 2024 Financial Results
CVM

Business Wire

a year ago

CEL-SCI Corporation Reports Third Quarter Fiscal 2024 Financial Results

CVM

Associated Press Finance

a year ago

Cel-Sci: Fiscal Q3 Earnings Snapshot

CEL-SCI Announces Closing of $10.8 Million Offering
CVM

Business Wire

a year ago

CEL-SCI Announces Closing of $10.8 Million Offering

CVM

MT Newswires

a year ago

Cel-Sci Prices $10.8 Million Offering

CEL-SCI Announces Pricing of $10.8 Million Offering
CVM

Business Wire

a year ago

CEL-SCI Announces Pricing of $10.8 Million Offering

CEL-SCI’s Phase 3 Population Analysis for Upcoming Confirmatory Registration Study in Head & Neck Cancer Demonstrates Well Balanced Patient Population, Confidence in Clinical Results
CVM

Business Wire

a year ago

CEL-SCI’s Phase 3 Population Analysis for Upcoming Confirmatory Registration Study in Head & Neck Cancer Demonstrates Well Balanced Patient Population, Confidence in Clinical Results

CVM

MT Newswires

a year ago

Cel-Sci Appoints Robert Watson Board's Chair

CEL-SCI Appoints Robert Watson as Chairperson of the Board
CVM

Business Wire

a year ago

CEL-SCI Appoints Robert Watson as Chairperson of the Board

CEL-SCI Presents Head & Neck Cancer Data at Iddst Annual Congress in Budapest: Risk of Death Cut in Half for Patients Treated With Multikine in the Target Population
CVM

Business Wire

a year ago

CEL-SCI Presents Head & Neck Cancer Data at Iddst Annual Congress in Budapest: Risk of Death Cut in Half for Patients Treated With Multikine in the Target Population

Italian energy company targets Britain for fleet of 20 mini-nukes
CVM

The Telegraph

a year ago

Italian energy company targets Britain for fleet of 20 mini-nukes

It Might Not Be A Great Idea To Buy StepStone Group LP (NASDAQ:STEP) For Its Next Dividend
CVM

Simply Wall St.

a year ago

It Might Not Be A Great Idea To Buy StepStone Group LP (NASDAQ:STEP) For Its Next Dividend

Is Now The Time To Put Planet Fitness (NYSE:PLNT) On Your Watchlist?
CVM

Simply Wall St.

a year ago

Is Now The Time To Put Planet Fitness (NYSE:PLNT) On Your Watchlist?

Don't Buy Banc of California, Inc. (NYSE:BANC) For Its Next Dividend Without Doing These Checks
CVM

Simply Wall St.

a year ago

Don't Buy Banc of California, Inc. (NYSE:BANC) For Its Next Dividend Without Doing These Checks

4 Reasons to Buy Invesco QQQ Trust Like There's No Tomorrow
CVM

Motley Fool

a year ago

4 Reasons to Buy Invesco QQQ Trust Like There's No Tomorrow

Should You Be Adding Mueller Water Products (NYSE:MWA) To Your Watchlist Today?
CVM

Simply Wall St.

a year ago

Should You Be Adding Mueller Water Products (NYSE:MWA) To Your Watchlist Today?

Seoul resumes loudspeaker propaganda against North
CVM

AFP

a year ago

Seoul resumes loudspeaker propaganda against North

Graham Full Year 2024 Earnings: EPS: US$0.42 (vs US$0.035 in FY 2023)
CVM

Simply Wall St.

a year ago

Graham Full Year 2024 Earnings: EPS: US$0.42 (vs US$0.035 in FY 2023)

Spirit Airlines not considering Chapter 11 bankruptcy, CNBC reports
CVM

Reuters

a year ago

Spirit Airlines not considering Chapter 11 bankruptcy, CNBC reports

Decisions of the Ordinary General Shareholders' Meeting of Novaturas AB
CVM

GlobeNewswire

a year ago

Decisions of the Ordinary General Shareholders' Meeting of Novaturas AB

AllianceBernstein: Office Space: Looking Past the Doom and Gloom
CVM

ACCESSWIRE

a year ago

AllianceBernstein: Office Space: Looking Past the Doom and Gloom

Moderna Files FDA Application for the JN.1 Targeting COVID-19 Vaccine
CVM

ACCESSWIRE

a year ago

Moderna Files FDA Application for the JN.1 Targeting COVID-19 Vaccine

Sage Potash Grants Stock Options
CVM

CNW Group

a year ago

Sage Potash Grants Stock Options

Aqua-Tots Swim School Splashes Into Summer With Highly-Anticipated Grand Opening in Henderson, Nevada
CVM

GlobeNewswire

a year ago

Aqua-Tots Swim School Splashes Into Summer With Highly-Anticipated Grand Opening in Henderson, Nevada

BW Energy: Mandatory notifications of trade by primary insiders and close associates
CVM

GlobeNewswire

a year ago

BW Energy: Mandatory notifications of trade by primary insiders and close associates

DaBaby and Stunna 4 Vegas's "NO DRIBBLE" Joins Music Licensing, Inc.'s Portfolio
CVM

Newsfile

a year ago

DaBaby and Stunna 4 Vegas's "NO DRIBBLE" Joins Music Licensing, Inc.'s Portfolio

Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor
CVM

Business Wire

a year ago

Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor

CVM: Confirmatory Study Clarity
CVM

Zacks Small Cap Research

a year ago

CVM: Confirmatory Study Clarity

CVM

Associated Press Finance

a year ago

Cel-Sci: Fiscal Q2 Earnings Snapshot

CEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial Results
CVM

Business Wire

a year ago

CEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial Results

CVM

MT Newswires

a year ago

Cel-Sci Gets US FDA Clearance to Proceed With Confirmatory Study for Cancer Drug Multikine

CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer
CVM

Business Wire

a year ago

CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer

CEL-SCI Appoints Mario Gobbo to Its Board of Directors
CVM

Business Wire

a year ago

CEL-SCI Appoints Mario Gobbo to Its Board of Directors

CVM

Zacks Small Cap Research

a year ago

CVM: Parallel Engagement on Four Fronts

CEL-SCI’s LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology
CVM

Business Wire

a year ago

CEL-SCI’s LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology

CEL-SCI Corporation Issues Letter to Shareholders
CVM

Business Wire

a year ago

CEL-SCI Corporation Issues Letter to Shareholders

CEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial Results
CVM

Business Wire

2 years ago

CEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial Results

CVM

Associated Press Finance

2 years ago

Cel-Sci: Fiscal Q1 Earnings Snapshot

CEL-SCI Announces Closing of $7.75 Million Public Offering of Common Stock
CVM

Business Wire

2 years ago

CEL-SCI Announces Closing of $7.75 Million Public Offering of Common Stock

CEL-SCI Announces Pricing of $7.75 Million Public Offering of Common Stock
CVM

Business Wire

2 years ago

CEL-SCI Announces Pricing of $7.75 Million Public Offering of Common Stock

CEL-SCI Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head & Neck Cancer Drug
CVM

Business Wire

2 years ago

CEL-SCI Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head & Neck Cancer Drug

European Medicines Agency Grants CEL-SCI a Waiver of Strict Pediatric Requirements, Clearing the Path Towards Marketing Authorization for Multikine®
CVM

Business Wire

2 years ago

European Medicines Agency Grants CEL-SCI a Waiver of Strict Pediatric Requirements, Clearing the Path Towards Marketing Authorization for Multikine®

USCB Financial Holdings, Inc. Initiates Quarterly Cash Dividend Program and Announces Declaration of First Cash Dividend
CVM

GlobeNewswire

2 years ago

USCB Financial Holdings, Inc. Initiates Quarterly Cash Dividend Program and Announces Declaration of First Cash Dividend

Franklin Financial Services (NASDAQ:FRAF) Will Pay A Dividend Of $0.32
CVM

Simply Wall St.

2 years ago

Franklin Financial Services (NASDAQ:FRAF) Will Pay A Dividend Of $0.32

Bassett Furniture Industries Inc (BSET) Reports Fiscal Q4 Earnings Amidst Market Challenges
CVM

GuruFocus.com

2 years ago

Bassett Furniture Industries Inc (BSET) Reports Fiscal Q4 Earnings Amidst Market Challenges

CVM

Business Wire

2 years ago

Mytheresa Announces Second Quarter of Fiscal Year 2024 Earnings Release and Conference Call; Participating in Upcoming Investor Conferences

eGain to Announce Fiscal 2024 Second Quarter Financial Results on February 8, 2024
CVM

GlobeNewswire

2 years ago

eGain to Announce Fiscal 2024 Second Quarter Financial Results on February 8, 2024

Wayfair (W) Soars 10.3%: Is Further Upside Left in the Stock?
CVM

Zacks

2 years ago

Wayfair (W) Soars 10.3%: Is Further Upside Left in the Stock?

Shareholders in Lifetime Brands (NASDAQ:LCUT) are in the red if they invested three years ago
CVM

Simply Wall St.

2 years ago

Shareholders in Lifetime Brands (NASDAQ:LCUT) are in the red if they invested three years ago

Profound Medical Announces Non-Brokered Private Placement
CVM

GlobeNewswire

2 years ago

Profound Medical Announces Non-Brokered Private Placement

FARO Technologies Announces CFO Transition
CVM

PR Newswire

2 years ago

FARO Technologies Announces CFO Transition

Is Erasca (NASDAQ:ERAS) In A Good Position To Invest In Growth?
CVM

Simply Wall St.

2 years ago

Is Erasca (NASDAQ:ERAS) In A Good Position To Invest In Growth?

Oatly Launches Two New Oatmilk Varieties, Marking the Company’s First Major Innovations to its Core North American Beverage Portfolio in Five Years
CVM

GlobeNewswire

2 years ago

Oatly Launches Two New Oatmilk Varieties, Marking the Company’s First Major Innovations to its Core North American Beverage Portfolio in Five Years

CVM

Zacks Small Cap Research

2 years ago

CVM: Fiscal Year 2023 in Review

Molecular Partners and Orano Med Announce Co-Development Agreement for Radio-DARPin Therapies
CVM

GlobeNewswire

2 years ago

Molecular Partners and Orano Med Announce Co-Development Agreement for Radio-DARPin Therapies

Verrica Pharmaceuticals Announces Last Patient Dosed in Part 2 of Phase 2 Study of VP-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma
CVM

GlobeNewswire

2 years ago

Verrica Pharmaceuticals Announces Last Patient Dosed in Part 2 of Phase 2 Study of VP-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma

Low-Cost, High-Potential: 3 Stocks Under $5 with Surprising Upside
CVM

InvestorPlace

2 years ago

Low-Cost, High-Potential: 3 Stocks Under $5 with Surprising Upside

CEL-SCI Reports Fiscal 2023 Financial Results and Clinical & Corporate Developments
CVM

Business Wire

2 years ago

CEL-SCI Reports Fiscal 2023 Financial Results and Clinical & Corporate Developments

Share on Social Networks: